* Molecular Templates Inc MTEM.OQ MTEM.O is expected to show
a rise in quarterly revenue when it reports results on November
3 (estimated).
* The Austin, Texas-based company is expected to report a
182.2% increase in revenue to $12.127 million from $4.3 million
a year ago, according to the mean estimate from 7 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Molecular Templates Inc
is for a loss of 38 cents per share. For the same quarter last
year, the company reported a loss of 47 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Molecular
Templates Inc is $13, about 57.4% above its last closing price
of $5.54.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Jun. 302021 -0.24 -0.27 -0.28 Missed -1.8
Mar. 312021 0.19 0.14 -0.51 Missed -454.8
Dec. 312020 -0.47 -0.42 -0.53 Missed -26.3
Sep. 302020 -0.56 -0.55 -0.47 Beat 14.8
Jun. -0.68 -0.48 -0.65 Missed -34.9
302020
Mar. 312020 -0.35 -0.32 -0.48 Missed -50.7
Dec. 312019 -0.18 -0.25 -0.41 Missed -61.4
Sep. 302019 -0.21 -0.24 -0.44 Missed -86.4
This summary was machine generated November 1 at 22:59 GMT. All
figures in US dollars unless otherwise stated